Topiramate-13C6 | 1217455-55-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氧吡喃
• 英文名称: Topiramate-13C6
• 英文别名: (4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.02,6]dodecan-6-yl)methyl sulfamate
• CAS: 1217455-55-4
• 化学式: C₁₂H₂₁NO₈S
• 分子量: 339.36
• InChiKey: KJADKKWYZYXHBB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  124
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• Topiramate salts and compositions comprising and methods of making and using the same
  申请人：——

  公开号：US20040053853A1

  公开（公告）日：2004-03-18

  The invention encompasses novel salts of topiramate, and pharmaceutically acceptable polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, or amorphous forms thereof, as well as pharmaceutical compositions and pharmaceutical unit dosage forms containing the same. In particular, the invention encompasses pharmaceutically acceptable salts of topiramate, including without limitation topiramate sodium, topiramate lithium, topiramate potassium, or polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, and amorphous forms thereof. The invention further encompasses novel co-crystals or complexes of topiramate, as well as pharmaceutical compositions comprising them. The invention also encompasses methods of treating or preventing a variety of diseases and conditions including, but not limited to, seizures, epileptic conditions, tremors, cerebral function disorders, obesity, neuropathic pain, affective disorders, tobacco cessation, migraines, and cluster headache.

  本发明涵盖了新型托吡酯盐，以及药学上可接受的多晶型、溶剂和水合物、脱水物、共晶体、无水物或非晶态形式，以及包含它们的制药组合物和制药剂量形式。特别地，本发明涵盖了托吡酯的药学上可接受的盐，包括但不限于托吡酯钠、托吡酯锂、托吡酯钾，或者它们的多晶型、溶剂和水合物、脱水物、共晶体、无水物和非晶态形式。本发明还涵盖了托吡酯的新型共晶体或复合物，以及包含它们的制药组合物。本发明还涵盖了治疗或预防各种疾病和病况的方法，包括但不限于癫痫、癫痫症状、震颤、脑功能障碍、肥胖症、神经病性疼痛、情感障碍、戒烟、偏头痛和丛集性头痛。
• Topiramate salts and compositions comprising them
  申请人：——

  公开号：US20030166581A1

  公开（公告）日：2003-09-04

  The invention encompasses novel salts of topiramate, and pharmaceutically acceptable polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, or amorphous forms thereof, as well as pharmaceutical compositions and pharmaceutical unit dosage forms containing the same. In particular, the invention encompasses pharmaceutically acceptable salts of topiramate, including without limitation topiramate sodium, topiramate lithium, topiramate potassium, or polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, and amorphous forms thereof. The invention further encompasses novel co-crystals or complexes of topiramate, as well as pharmaceutical compositions comprising them. The invention also encompasses methods of treating or preventing a variety of diseases and conditions including, but not limited to, seizures, epileptic conditions, tremors, cerebral function disorders, obesity, neuropathic pain, affective disorders, tobacco cessation, migraines, and cluster headache.

  本发明涵盖了托吡酯的新型盐，以及其药学上可接受的多形态、溶剂化物、水合物、脱水物、共晶体、无水物或非晶态形式，以及包含它们的制药组合物和制药剂量形式。特别地，本发明涵盖了托吡酯的药学上可接受的盐，包括但不限于托吡酯钠、托吡酯锂、托吡酯钾或其多形态、溶剂化物、水合物、脱水物、共晶体、无水物和非晶态形式。本发明还涵盖了托吡酯的新型共晶体或复合物，以及包含它们的制药组合物。本发明还涵盖了治疗或预防多种疾病和症状的方法，包括但不限于癫痫、癫痫症状、震颤、脑功能障碍、肥胖症、神经病性疼痛、情感障碍、戒烟、偏头痛和集群性头痛。
• US6699840B2
  申请人：——

  公开号：US6699840B2

  公开（公告）日：2004-03-02
• US7351695B2
  申请人：——

  公开号：US7351695B2

  公开（公告）日：2008-04-01